Tag: DESTINY-CRC01

DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC

Presented By
Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan
Trial
Phase 2, DESTINY-CRC01
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 10:26

Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Presented By
Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan
Trial
Phase 2, DESTINY-CRC01
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 21:10

HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

Expert
Prof. Salvatore Siena, University of Milan Niguarda Cancer Center, Italy
Trial
Phase 3, DESTINY-CRC01
Conference
ASCO 2020

17 September 2020 15:00
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com